374 related articles for article (PubMed ID: 10606240)
21. Comparative chemopreventive activity of ibuprofen and N-(4-hydroxyphenyl) retinamide against the development and growth of rat mammary adenocarcinomas.
Alshafie GA; Harris RE; Robertson FM; Parrett ML; Ross M; Abou-Issa H
Anticancer Res; 1999; 19(4B):3031-6. PubMed ID: 10652588
[TBL] [Abstract][Full Text] [Related]
22. Retinol metabolism and lecithin:retinol acyltransferase levels are reduced in cultured human prostate cancer cells and tissue specimens.
Guo X; Knudsen BS; Peehl DM; Ruiz A; Bok D; Rando RR; Rhim JS; Nanus DM; Gudas LJ
Cancer Res; 2002 Mar; 62(6):1654-61. PubMed ID: 11912136
[TBL] [Abstract][Full Text] [Related]
23. Effects of N-(4-hydroxyphenyl)-retinamide on the number and cytotoxicity of natural killer cells in vitamin-A-sufficient and -deficient rats.
Zhao Z; Matsuura T; Popoff K; Ross AC
Nat Immun; 1994; 13(5):280-8. PubMed ID: 7833627
[TBL] [Abstract][Full Text] [Related]
24. Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide.
Pienta KJ; Nguyen NM; Lehr JE
Cancer Res; 1993 Jan; 53(2):224-6. PubMed ID: 7678070
[TBL] [Abstract][Full Text] [Related]
25. Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines.
Tanabe T
Hiroshima J Med Sci; 2000 Mar; 49(1):67-72. PubMed ID: 10824459
[TBL] [Abstract][Full Text] [Related]
26. N-(4-hydroxyphenyl)retinamide (fenretinide) induces retinol-binding protein secretion from liver and accumulation in the kidneys in rats.
Schaffer EM; Ritter SJ; Smith JE
J Nutr; 1993 Sep; 123(9):1497-503. PubMed ID: 8360775
[TBL] [Abstract][Full Text] [Related]
27. Antitumor activity of 4-(N-hydroxyphenyl)retinamide conjugated with poly(L-glutamic acid) against ovarian cancer xenografts.
Zou C; Brewer M; Cao X; Zang R; Lin J; Deng Y; Li C
Gynecol Oncol; 2007 Dec; 107(3):441-9. PubMed ID: 17854871
[TBL] [Abstract][Full Text] [Related]
28. Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome.
Formelli F; Camerini T; Cavadini E; Appierto V; Villani MG; Costa A; De Palo G; Di Mauro MG; Veronesi U
Cancer Epidemiol Biomarkers Prev; 2003 Jan; 12(1):34-41. PubMed ID: 12540501
[TBL] [Abstract][Full Text] [Related]
29. N-(4-hydroxyphenyl) retinamide is anticlastogenic in human lymphoblastoid cell lines.
Trizna Z; Benner SE; Shirley L; Furlong C; Hong WK
Anticancer Res; 1993; 13(2):355-6. PubMed ID: 7685988
[TBL] [Abstract][Full Text] [Related]
30. Retinol-binding protein secretion from the liver of N-(4-hydroxyphenyl) retinamide-treated rats.
Ritter SJ; Smith JE
Biochim Biophys Acta; 1996 Jun; 1290(2):157-64. PubMed ID: 8645719
[TBL] [Abstract][Full Text] [Related]
31. N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase.
Wang H; Maurer BJ; Reynolds CP; Cabot MC
Cancer Res; 2001 Jul; 61(13):5102-5. PubMed ID: 11431347
[TBL] [Abstract][Full Text] [Related]
32. Fenretinide and its relation to cancer.
Ulukaya E; Wood EJ
Cancer Treat Rev; 1999 Aug; 25(4):229-35. PubMed ID: 10448131
[TBL] [Abstract][Full Text] [Related]
33. Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line.
Appierto V; Cavadini E; Pergolizzi R; Cleris L; Lotan R; Canevari S; Formelli F
Br J Cancer; 2001 Jun; 84(11):1528-34. PubMed ID: 11384104
[TBL] [Abstract][Full Text] [Related]
34. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma.
Garaventa A; Luksch R; Lo Piccolo MS; Cavadini E; Montaldo PG; Pizzitola MR; Boni L; Ponzoni M; Decensi A; De Bernardi B; Bellani FF; Formelli F
Clin Cancer Res; 2003 Jun; 9(6):2032-9. PubMed ID: 12796365
[TBL] [Abstract][Full Text] [Related]
35. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
36. NTP Toxicology and Carcinogenesis Studies of Salicylazosulfapyridine (CAS No. 599-79-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1997 May; 457():1-327. PubMed ID: 12587019
[TBL] [Abstract][Full Text] [Related]
37. Secretion of N-(4-hydroxyphenyl) retinamide-retinol-binding protein from liver parenchymal cells: evidence for reduced affinity of the complex for transthyretin.
Holven KB; Natarajan V; Gundersen TE; Moskaug JO; Norum KR; Blomhoff R
Int J Cancer; 1997 May; 71(4):654-9. PubMed ID: 9178822
[TBL] [Abstract][Full Text] [Related]
38. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
39. Effects of pretreatment with the retinoid N-(4-hydroxyphenyl)-all-trans-retinamide and phenobarbital on the disposition and metabolism of N-(4-hydroxyphenyl)-all-trans-retinamide in mice.
Hultin TA; McCormick DL; May CM; Moon RC
Drug Metab Dispos; 1988; 16(6):783-8. PubMed ID: 2907453
[TBL] [Abstract][Full Text] [Related]
40. Effect of N-(4-hydroxyphenyl)retinamide on murine mammary tumor cells in culture.
Bunk MJ; Telang NT; Higgins PJ; Traganos F; Sarkar NH
Nutr Cancer; 1985; 7(1-2):105-15. PubMed ID: 2999720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]